Abu Dhabi:The Department of Health - Abu Dhabi (DoH) has signed agreements with several key partners to further research in life sciences, personalized preventive health, and AI-driven drug discovery. The agreements were signed in the presence of H.H. Sheikh Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes' Affairs, with collaborations including Isomorphic Labs, WHOOP, Cleveland Clinic Abu Dhabi, and AstraZeneca.
According to Wam, DoH and Isomorphic Labs have entered into a partnership to focus on AI-enabled drug discovery research. The agreement, signed at the Abu Dhabi Future Health Summit, aims to develop a roadmap for selected AI-enabled discovery projects over 24 months. The research will take place within Abu Dhabi's Trusted Research Environment, utilizing Isomorphic Labs' IsoDDE, a drug design engine based on AI models.
The collaboration with WHOOP focuses on preventive health through continuous health insights and coaching. Mansoor Ibrahim Al Mansoori, Chairman of DoH, and Will Ahmed, Founder and CEO of WHOOP, signed the agreement, which will involve a phased programme on heart and metabolic health, utilizing WHOOP's wearable technology. The research aims to transform health data into personalized guidance to improve health outcomes.
Additionally, DoH has joined forces with Cleveland Clinic Abu Dhabi and AstraZeneca to position Abu Dhabi as a key location in AstraZeneca's global clinical trial network. This collaboration will potentially lead to 30 clinical trials in Abu Dhabi by 2030, focusing on cardiovascular, renal, and metabolic diseases. The initiative is expected to inject AED180 million (US$50 million) into local life sciences research by 2030.
These collaborations underscore Abu Dhabi's commitment to advancing health research through the integration of AI, genomics, and digital health, aiming to enhance patient care both locally and globally.
Source Wam